PL3846788T3 - Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona - Google Patents
Inhibitory pde11 do zastosowania w leczeniu choroby parkinsonaInfo
- Publication number
- PL3846788T3 PL3846788T3 PL19783154.8T PL19783154T PL3846788T3 PL 3846788 T3 PL3846788 T3 PL 3846788T3 PL 19783154 T PL19783154 T PL 19783154T PL 3846788 T3 PL3846788 T3 PL 3846788T3
- Authority
- PL
- Poland
- Prior art keywords
- parkinson
- disease
- treatment
- pde11 inhibitors
- pde11
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192799 | 2018-09-05 | ||
| PCT/NL2019/050578 WO2020050722A1 (en) | 2018-09-05 | 2019-09-05 | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3846788T3 true PL3846788T3 (pl) | 2026-02-23 |
Family
ID=63517803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19783154.8T PL3846788T3 (pl) | 2018-09-05 | 2019-09-05 | Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210330736A1 (pl) |
| EP (1) | EP3846788B1 (pl) |
| JP (2) | JP2021535180A (pl) |
| CN (1) | CN112996492A (pl) |
| DK (1) | DK3846788T3 (pl) |
| ES (1) | ES3058213T3 (pl) |
| FI (1) | FI3846788T3 (pl) |
| PL (1) | PL3846788T3 (pl) |
| WO (1) | WO2020050722A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116173035A (zh) * | 2021-11-26 | 2023-05-30 | 中国科学院深圳先进技术研究院 | 双嘧达莫在抑制Mcl-1中的应用 |
| WO2025075499A1 (en) * | 2023-10-02 | 2025-04-10 | Universiteit Van Amsterdam | Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0967284A1 (en) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| AU2001255849B8 (en) * | 2000-04-19 | 2006-04-27 | Lilly Icos, Llc. | PDE-V inhibitors for treatment of Parkinson's Disease |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| FR2846653B1 (fr) * | 2002-10-30 | 2007-04-20 | Neuro3D | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| JP2007501866A (ja) | 2003-06-13 | 2007-02-01 | マイクロバイア インコーポレイテッド | 胃腸疾患の治療のための方法および組成物 |
| WO2005041957A1 (en) * | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| WO2007142929A2 (en) * | 2006-05-31 | 2007-12-13 | The University Of North Carolina At Chapel Hill | Novel pde4 inhibitors |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| WO2008119057A2 (en) * | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
| EP2282779B1 (en) * | 2008-04-29 | 2013-03-13 | Pharnext | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
| US8748575B2 (en) | 2010-06-09 | 2014-06-10 | Combimab, Inc. | Therapeutic peptides |
| US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| WO2013082275A1 (en) * | 2011-11-30 | 2013-06-06 | Trustees Of Boston College | Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production |
| EA034689B1 (ru) * | 2012-04-27 | 2020-03-06 | Милленниум Фармасьютикалз, Инк. | Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии |
| JP2013241354A (ja) * | 2012-05-18 | 2013-12-05 | Oriza Yuka Kk | ホスホジエステラーゼ2阻害剤 |
| US9849132B2 (en) * | 2014-01-08 | 2017-12-26 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
| WO2016145614A1 (en) * | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
-
2019
- 2019-09-05 PL PL19783154.8T patent/PL3846788T3/pl unknown
- 2019-09-05 FI FIEP19783154.8T patent/FI3846788T3/fi active
- 2019-09-05 ES ES19783154T patent/ES3058213T3/es active Active
- 2019-09-05 CN CN201980066363.6A patent/CN112996492A/zh active Pending
- 2019-09-05 WO PCT/NL2019/050578 patent/WO2020050722A1/en not_active Ceased
- 2019-09-05 JP JP2021512542A patent/JP2021535180A/ja active Pending
- 2019-09-05 DK DK19783154.8T patent/DK3846788T3/da active
- 2019-09-05 US US17/271,978 patent/US20210330736A1/en active Pending
- 2019-09-05 EP EP19783154.8A patent/EP3846788B1/en active Active
-
2024
- 2024-07-12 JP JP2024112678A patent/JP2024138492A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3846788T3 (da) | 2026-01-12 |
| EP3846788B1 (en) | 2025-10-29 |
| EP3846788A1 (en) | 2021-07-14 |
| FI3846788T3 (fi) | 2025-12-17 |
| JP2024138492A (ja) | 2024-10-08 |
| WO2020050722A1 (en) | 2020-03-12 |
| US20210330736A1 (en) | 2021-10-28 |
| CN112996492A (zh) | 2021-06-18 |
| ES3058213T3 (en) | 2026-03-09 |
| JP2021535180A (ja) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| HRP20251604T1 (hr) | Antagonist gremlina‑1 za upotrebu u liječenju raka | |
| IL259862B (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| IL287745A (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL283654A (en) | Decarboxylase inhibitors for the treatment of Parkinson's disease | |
| ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
| PL3846788T3 (pl) | Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona | |
| IL275132A (en) | C5AR inhibitors for use in the treatment of iatrogenic pain caused by chemotherapy | |
| PL3458045T3 (pl) | Ebselen do zastosowania w leczeniu choroby meniere’a | |
| PT3413870T (pt) | Igmesina para utilização no tratamento de doença de alzheimer | |
| IL286818A (en) | Mirikizumab for use in a method of treating crohns disease | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IT201600122310A1 (it) | Composizione per uso nella terapia di alterazioni dell'intestino | |
| PT3448430T (pt) | Uso de inibidores da acetilcolinesterase e idalopirdina para reduzir quedas em doentes com doença de parkinson | |
| ITUA20163037A1 (it) | Formulazioni per uso nel trattamento o prevenzione di disturbi urologici | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| DK3423081T3 (da) | Sammensætninger til brug i behandlingen af neurologisk sygdom |